Allogene Therapeutics (ALLO, Financial) experienced a notable stock price increase of 5%, bringing the price to $2.71 with a trading volume of 709,175 shares and a turnover rate of 0.34%. The stock's price fluctuation reached 5.23%.
In its latest financial report, Allogene Therapeutics recorded no revenue and reported a net loss of $66.36 million. The company's earnings per share were -$0.35, with a gross loss of $3.64 million, and it holds a negative price-to-earnings ratio of -1.70. Among 18 institutions that rated the stock, 72% recommended it as a 'buy', and 28% suggested 'hold', with no 'sell' recommendations.
The broader biotech sector saw a modest increase of 0.11%. Within the sector, significant gainers included Nkgen Biotech Inc, Portage Biotech Inc, and Hcw Biologics Inc. Other active stocks were Aditxt, Inc., Bio-Path Holdings, Inc., and Gri Bio, Inc., with turnover rates of 2511.04%, 2440.06%, and 259.98%, respectively. Notably, stocks with high volatility include Nkgen Biotech Inc with a 66.06% fluctuation, Bio-Path Holdings, Inc. at 57.39%, and Virios Therapeutics, Inc. at 46.27%.
Allogene Therapeutics is a clinical-stage biotechnology company specializing in immuno-oncology. They develop engineered allogeneic T cell products aimed at cancer and autoimmune diseases. Their approach leverages healthy donor cells for broader patient eligibility and scalability, focusing on cancers like lymphoma, leukemia, and autoimmune diseases, with income derived from collaborations and licensing agreements.
